Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced...
- Day's Range
- 0.290 - 0.320
- 52 wk Range
- 0.250 - 7.700
- Prev. Close
- Average Vol.(3m)
- 1-Year Change
- Market Cap
- P/E Ratio
- United States
- Shares Outstanding
- Dividend (Yield)
- N/A (N/A%)
- Next Earnings Date
- Nov 09, 2023
Investing.com - Eiger Biopharma (NASDAQ: EIGR) reported second quarter EPS of $-0.470, $0.08 worse than the analyst estimate of $-0.390. Revenue for the quarter came in at $4.64M versus the...
An analyst from Baird maintained Eiger Biopharma (NASDAQ: EIGR) at 'outperform' with a price target of $5.00 from a prior price target of $3.00. Prior to this rating, Eiger Biopharma had 3...
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that...
Investing.com - Eiger Biopharma (NASDAQ: EIGR) reported first quarter EPS of $-0.520, $0.10 worse than the analyst estimate of $-0.420. Revenue for the quarter came in at $4.12M versus the...
Investing.com - Eiger Biopharma (NASDAQ: EIGR) reported first quarter EPS of $-0.570, $0.04 worse than the analyst estimate of $-0.530. Revenue for the quarter came in at $2.7M versus the...
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Oil & Gas, Basic Materials and Industrials sectors propelled shares lower. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.